Contact
searchSearch
HMP Global
Login

News

FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
Thomas Powles, MBBS, MD
Conference Coverage
Continued Efficacy With Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
02/18/2025
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS,...
02/18/2025
Oncology
Conference Coverage
Durvalumab Plus Intravesical Chemotherapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
02/13/2025
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the...
02/13/2025
Oncology
News
Enfortumab Vedotin Demonstrates Real-World Efficacy Among Patients With Metastatic Urothelial Carcinoma
12/13/2024
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a...
12/13/2024
Oncology
News
Optimal Disitamab Vedotin Dose for Patients With Chemotherapy-Refractory Advanced Urothelial Carcinoma
12/13/2024
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the...
12/13/2024
Oncology
News
Adjuvant PD-1/-L1 Inhibition Significantly Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma Regardless of PD-L1 Status
12/09/2024
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with...
12/09/2024
Oncology
News
Real-World Efficacy of Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma
12/04/2024
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective...
12/04/2024
Oncology
News
Pembrolizumab Plus Gemcitabine-Platinum Doublet Chemotherapy Improves Survival Regardless of Platinum Agent for Urothelial Carcinoma
11/19/2024
Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...
Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...
Subset analysis results from the...
11/19/2024
Oncology
News
UGN-102 Chemoablation as TURBT Alternative for Patients With Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer
11/19/2024
According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...
According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...
According to results from the...
11/19/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use